X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Capsida
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 15, 2021
Details:
Under the agreement, CRISPR Therapeutics will lead R&D of the Friedreich’s ataxia program and perform gene-editing activities for both programs, and Capsida will lead research and development of the ALS program and conduct AAV vectors engineering for both programs.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
